Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The MHCII Immune Activation Score predicts risk of recurrence and benefit of taxanes in Basal-like and HER2-enriched breast cancer.

medRxiv : the preprint server for health sciences·2026
Same author

Frequent Sweetened Beverage Consumption Is Associated With Accelerated Biological Aging: Evidence From a Population-Based Study and Gut Microbiota Analysis.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Association of cancer antigen 15-3 with distant recurrence in immunohistochemically defined breast cancer subtypes in Canadian Cancer Trials Group MA.32.

JNCI cancer spectrum·2026
Same author

A phase 1 study of R-GDP-venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18).

Blood neoplasia·2026
Same author

Helicobacter pylori infection and metabolic dysfunction-associated steatotic liver disease: a prospective study and meta-analysis.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

Associations of dietary diversity with type 2 diabetes in two Chinese cohorts: a multi-omics study.

Food & function·2026

Related Experiment Video

Updated: Jul 8, 2026

Isolation, Culture, and Characterization of Prostate Cancer-Associated Fibroblasts
09:43

Isolation, Culture, and Characterization of Prostate Cancer-Associated Fibroblasts

Published on: August 1, 2025

TNF polymorphisms and prostate cancer risk.

Kim N Danforth1, Carmen Rodriguez, Richard B Hayes

  • 1Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, Maryland 20852, USA.

The Prostate
|January 16, 2008
PubMed
Summary

This study investigated the link between tumor necrosis factor (TNF) gene variants and prostate cancer risk. Researchers found no significant association between TNF single nucleotide polymorphisms (SNPs) and prostate cancer.

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Related Experiment Videos

Last Updated: Jul 8, 2026

Isolation, Culture, and Characterization of Prostate Cancer-Associated Fibroblasts
09:43

Isolation, Culture, and Characterization of Prostate Cancer-Associated Fibroblasts

Published on: August 1, 2025

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Area of Science:

  • Genetics
  • Oncology
  • Molecular Epidemiology

Background:

  • Inflammation is a suspected factor in prostate cancer development.
  • Tumor necrosis factor (TNF) is a key inflammatory mediator.
  • The specific role of TNF genetic variants in prostate cancer risk is not well understood.

Purpose of the Study:

  • To investigate the association between specific tumor necrosis factor (TNF) gene variants and the risk of developing prostate cancer.
  • To analyze the relationship between six TNF single nucleotide polymorphisms (SNPs) and prostate cancer incidence.

Main Methods:

  • Examined associations between six TNF single nucleotide polymorphisms (SNPs) and prostate cancer risk.
  • Utilized two nested case-control studies: the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) and the Cancer Prevention Study II Nutrition Cohort.
  • Estimated odds ratios and confidence intervals for individual SNPs and haplotypes in separate and pooled analyses.

Main Results:

  • No significant association was found between individual TNF SNPs and prostate cancer risk in the PLCO cohort or in pooled analyses.
  • Two correlated TNF variants showed marginal associations in the Nutrition Cohort (P-trend = 0.04 and 0.02).
  • Haplotype analyses revealed marginal associations in the Nutrition Cohort and pooled analyses (global P = 0.06 and 0.05, respectively) after adjustment for multiple testing.

Conclusions:

  • The study did not find conclusive evidence supporting a link between TNF variants and prostate cancer risk.
  • While some haplotype results were suggestive, overall findings do not establish a significant association.
  • Further research may be needed to fully elucidate the role of TNF in prostate cancer etiology.